NO20052426L - Fremgangsmater for vaksinasjon mot malaria - Google Patents

Fremgangsmater for vaksinasjon mot malaria

Info

Publication number
NO20052426L
NO20052426L NO20052426A NO20052426A NO20052426L NO 20052426 L NO20052426 L NO 20052426L NO 20052426 A NO20052426 A NO 20052426A NO 20052426 A NO20052426 A NO 20052426A NO 20052426 L NO20052426 L NO 20052426L
Authority
NO
Norway
Prior art keywords
methods
against malaria
vaccination against
based vaccine
protein
Prior art date
Application number
NO20052426A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052426D0 (no
Inventor
Joseph Cohen
Stephen L Hoffman
Ruobing Wang
Judith E Epstein
Original Assignee
Us Navy Naval Med Res Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Navy Naval Med Res Ct filed Critical Us Navy Naval Med Res Ct
Publication of NO20052426D0 publication Critical patent/NO20052426D0/no
Publication of NO20052426L publication Critical patent/NO20052426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20052426A 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria NO20052426L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42026502P 2002-10-23 2002-10-23
US44702603P 2003-02-13 2003-02-13
PCT/US2003/033462 WO2004037189A2 (fr) 2002-10-23 2003-10-22 Methodes de vaccination contre le paludisme

Publications (2)

Publication Number Publication Date
NO20052426D0 NO20052426D0 (no) 2005-05-19
NO20052426L true NO20052426L (no) 2005-05-19

Family

ID=32179789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052426A NO20052426L (no) 2002-10-23 2005-05-19 Fremgangsmater for vaksinasjon mot malaria

Country Status (11)

Country Link
US (1) US8232255B2 (fr)
EP (2) EP2277533B1 (fr)
JP (2) JP5404990B2 (fr)
AU (2) AU2003285932A1 (fr)
CA (1) CA2502268A1 (fr)
ES (1) ES2594758T3 (fr)
NO (1) NO20052426L (fr)
NZ (1) NZ539509A (fr)
PL (1) PL376792A1 (fr)
RU (1) RU2356577C9 (fr)
WO (1) WO2004037189A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2003285932A1 (en) * 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
US8400408B2 (en) * 2007-06-13 2013-03-19 Apple Inc. Touch screens with transparent conductive material resistors
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2009071613A2 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccin
US8728492B2 (en) * 2008-01-18 2014-05-20 Aeras Global Tb Vaccine Foundation Malaria vaccine compositions and constituents which elicit cell mediated immunity
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2011022002A1 (fr) * 2009-08-18 2011-02-24 The Rockefeller University Modification d'adénovirus recombinant par des épitopes immunogènes de protéine circumsporozoïte de plasmodium
ES2641892T3 (es) * 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
EP2451477A4 (fr) * 2009-11-13 2013-08-14 Us Navy Epitopes de lymphocytes t restreints par les hla de classe i de plasmodium falciparum
BR112013004582A2 (pt) * 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
WO2012154199A1 (fr) * 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Protéine circumsporozoïte recombinante soluble de plasmodium falciparum,
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2014028644A1 (fr) * 2012-08-15 2014-02-20 Cyvax, Inc. Procédés et compositions pour la prévention d'un état
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2016059911A1 (fr) * 2014-10-17 2016-04-21 国立大学法人金沢大学 Vaccin antipaludéen
WO2017178809A1 (fr) 2016-04-12 2017-10-19 Oxford University Innovation Limited Cible d'immunisation
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン
CN110958886A (zh) * 2017-05-24 2020-04-03 埃克哈德·维尔纳 恶性疟原虫和间日疟原虫疫苗
WO2019086466A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
WO2019086450A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et ses utilisations
WO2019086461A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
CN111372943B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
CA2138997C (fr) 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
EP1167379A3 (fr) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Oligonucléotides immunomodulateurs
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302522C (fr) 1997-08-29 2010-08-17 Antigenics Llc Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
RU2178710C1 (ru) * 2001-02-08 2002-01-27 Кожемякин Леонид Андреевич Индивидуальные вещества, полученные на основе химического взаимодействия дисульфидсодержащих пептидов с производными пуриновых или пиримидиновых оснований, фармацевтические композиции и препараты на их основе, способы их применения для лечения инфекционных заболеваний и профилактики осложнений
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
AU2003285932A1 (en) * 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria

Also Published As

Publication number Publication date
EP2277533B1 (fr) 2016-07-20
JP5404990B2 (ja) 2014-02-05
NZ539509A (en) 2008-05-30
CA2502268A1 (fr) 2004-05-06
NO20052426D0 (no) 2005-05-19
WO2004037189A2 (fr) 2004-05-06
RU2005115837A (ru) 2006-01-20
US8232255B2 (en) 2012-07-31
EP1569515A2 (fr) 2005-09-07
EP2277533A2 (fr) 2011-01-26
WO2004037189A3 (fr) 2004-10-21
RU2356577C2 (ru) 2009-05-27
AU2003285932A1 (en) 2004-05-13
RU2356577C9 (ru) 2009-08-10
US20060188527A1 (en) 2006-08-24
PL376792A1 (pl) 2006-01-09
JP2006512405A (ja) 2006-04-13
AU2010200177A1 (en) 2010-02-04
ES2594758T3 (es) 2016-12-22
EP2277533A3 (fr) 2012-03-07
EP1569515A4 (fr) 2006-04-26
JP2011068671A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
NO20052426L (no) Fremgangsmater for vaksinasjon mot malaria
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
DK1618889T3 (da) Influenzavaccine
NO20051469L (no) Immunstimulerende nukleinsyrer.
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
WO2021155243A8 (fr) Compositions d'immunisation contre le virus respiratoire
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2004098491A3 (fr) Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
DK1263936T3 (da) andret stamme af den modificerede Vacciniavirus Ankara (MVA)
WO2003059385A3 (fr) Vaccin contre le vih et procede d'utilisation
WO2002036790A3 (fr) Vecteur de virus grippal destine a l'infection de cellules dendritiques
WO2005028496A3 (fr) Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
WO2009080715A3 (fr) Vaccins anti-malaria
WO2022137128A3 (fr) Arn messager auto-amplifiant
WO2003080112A3 (fr) Adjuvant
MXPA05012270A (es) Materiales y metodos para inmunizar en contra de la infeccion por virus de inmunodeficiencia de felino.
WO2003103570A3 (fr) Immunisation transcutanee contre le papillomavirus avec un virus de type papillomavirus
WO2005027844A3 (fr) Compositions issues d'un vaccin adn et leurs procedes d'utilisation
AU2003277909A1 (en) Recombinant mva strains as potential vaccines against p. falciparum malaria
EP1543165A4 (fr) Dosages de regroupement des nucleocapsides du virus ebola
WO2004034956A3 (fr) Production d'un vaccin vivant agissant contre des virus de la grippe
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania
DK1204421T3 (da) Stressprotein-peptidkomplekser som vacciner mod intracellulære patogener
ES2172482A1 (es) Adicion de la patente es 200100402 vacuna para la proteccion de perros frente a leishmania

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application